<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02583373</url>
  </required_header>
  <id_info>
    <org_study_id>CAL02-001</org_study_id>
    <nct_id>NCT02583373</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae</brief_title>
  <official_title>Randomised, Multicentre, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy and Pharmacodynamics After the Intravenous Administration of CAL02 in Severe Community-acquired Pneumonia Due to Streptococcus Pneumoniae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Combioxin SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Combioxin SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess the safety, tolerability, clinical and
      microbiological efficacy and pharmacodynamics of patients who have severe pneumonia caused by
      Streptococcus pneumoniae after the intravenous administration of CAL02 in addition of
      standard of care antibiotic treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Streptococcus pneumoniae is the most frequently identified pathogen of community-acquired
      bacterial pneumonia and its severe forms are associated with high morbidity and mortality,
      despite pneumococcal vaccines and medical treatment (antibiotic therapy, alone or in
      combination). Bacterial toxins, such as the pore-forming toxin (PFT) pneumolysin (from
      Streptococcus pneumoniae), are involved in the development of invasive disease and play a key
      role in severe and fatal complications. CAL02 offers a novel therapeutic approach by
      neutralising bacterial toxins, such as pneumolysin, which recognise specific microdomains on
      host cell membranes, called lipid rafts.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 21, 2016</start_date>
  <completion_date type="Actual">February 20, 2018</completion_date>
  <primary_completion_date type="Actual">February 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency, severity and characteristics of adverse events after two iv. administrations of CAL02.</measure>
    <time_frame>29 days</time_frame>
    <description>To determine the safety profile of CAL02</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy: cure.</measure>
    <time_frame>29 days.</time_frame>
    <description>Complete resolution of signs and symptoms of pneumonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effects.</measure>
    <time_frame>29 days.</time_frame>
    <description>Measuring biomarkers (CRP/PCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological efficacy.</measure>
    <time_frame>29 days.</time_frame>
    <description>Eradication: baseline isolate not present in repeat culture from original infection site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival.</measure>
    <time_frame>29 days</time_frame>
    <description>Assessment of 28 days all cause mortality.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Pneumonia</condition>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>CAL02 Low-dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liposomal formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAL02 High-dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liposomal formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAL02 Low-dose</intervention_name>
    <description>Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion</description>
    <arm_group_label>CAL02 Low-dose</arm_group_label>
    <other_name>CAL02 LD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAL02 High-dose</intervention_name>
    <description>Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion</description>
    <arm_group_label>CAL02 High-dose</arm_group_label>
    <other_name>CAL02 HD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered administered 2 times (24 hours apart) as i.v. infusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo CAL02</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male or female patients ≥ 18 years and ≤ 80 years of age

          -  Body weight 40-140 kg

          -  Severe pneumonia caused by Streptococcus pneumoniae managed in an ICU

          -  CURB-65 score ≥ 3 in patients aged &gt; 65 and CURB-65 ≥ 2 in patients aged &lt; 65

          -  Streptococcus pneumoniae identification with the urine antigen test or any other
             proven documented identification method

          -  Written informed consent provided by the patient, the relatives or the designated
             trusted person and/or according to local guidelines

        Exclusion Criteria:

          -  Patients with hospital-acquired-, health care-acquired- or ventilator-
             associated-pneumonia

          -  More than (i) 12 hours since diagnosis of severe CAPP and (ii) 24 hours or 60 hours
             since antibiotic treatment IV or per os, respectively, unless documented not to be
             active against S. pneumoniae, will have elapsed at the time of IMP administration

          -  APACHE II score &gt; 30 points

          -  SOFA score &gt; 12 points

          -  Inability to maintain a mean arterial pressure ≥ 50 mm Hg

          -  Known hypersensitivity to liposomal formulations

          -  Patients with severe neutropenia or lymphoma or current or anticipated chemotherapy

          -  End-stage neuromuscular disorders

          -  Patients who have long-term tracheostomy

          -  Current or recent participation in an investigational study

          -  Presence of other pneumococcal site infection

          -  Patients with known acquired immune deficiency syndrome (AIDS) with CD4 count &lt; 200
             cells/mL

          -  Patients with known post-obstructive pneumonia (active primary lung cancer or another
             malignancy metastatic to the lungs)

          -  Patients with cystic fibrosis, Pneumocystis jiroveci pneumonia, or active tuberculosis

          -  Patients receiving immunosuppressant therapy

          -  Patients with a known liver function deficiency

          -  Splenectomised patients

          -  Patients who have experienced an allergic reaction to eggs

          -  Moribund clinical condition

          -  Nursing and pregnant women

          -  Women of child bearing potential not using an effective contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BRUNO FRANCOIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Limoges CHU Dupuytren 2 Avenue Martin Luther King 87042 Limoges Cedex, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Luc University Hospital</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Brussels</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique St Pierre</name>
      <address>
        <city>Ottignies</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD Les Oudairies</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional d'ORLEANS</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Yves Le Foll</name>
      <address>
        <city>Saint-Brieuc</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2015</study_first_submitted>
  <study_first_submitted_qc>October 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumonia</keyword>
  <keyword>Streptococcus pneumoniae</keyword>
  <keyword>Pneumolysin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumococcal Infections</mesh_term>
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

